Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsors and Collaborators: |
Children's Hospital of Eastern Ontario The Physicians' Services Incorporated Foundation |
---|---|
Information provided by: | Children's Hospital of Eastern Ontario |
ClinicalTrials.gov Identifier: | NCT00867841 |
Pneumonia, or lung infection, is usually treated with antibiotics targeted against the organisms that the physician guesses are causing the problem. The determination of the exact cause of a patient's pneumonia is difficult. The problem is that the two major causes of community-acquired pneumonia are not easily distinguished on clinical grounds and are best treated by different antibiotics. The investigators hypothesize that antibiotic therapy can be targeted and improved by doing polymerase chain reaction (PCR) testing of nose swabs to identify probable implicated organisms and their antibiotic resistance patterns. This pilot study will be important to ensure that the laboratory testing is functional and that the emergency department-laboratory communication is optimal prior to doing a full-fledged randomized clinical trial.
Condition | Intervention |
---|---|
Pneumonia |
Procedure: nasopharyngeal swab |
Study Type: | Observational |
Study Design: | Ecologic or Community, Prospective |
Official Title: | A Polymerase Chain Reaction-Based Method to Improve Antibiotic Prescribing for Children and Adolescents With Community-Acquired Pneumonia - a Pilot Study |
nasopharyngeal swabs blood samples (for pneumococcal PCR)
Estimated Enrollment: | 100 |
Study Start Date: | April 2009 |
Estimated Study Completion Date: | June 2009 |
Estimated Primary Completion Date: | June 2009 (Final data collection date for primary outcome measure) |
Groups/Cohorts | Assigned Interventions |
---|---|
Pneumonia
Children diagnosed with community-acquired pneumonia by the emergency department physician
|
Procedure: nasopharyngeal swab
PCR of NP swab for Mycoplasma, Chlamydophila, pneumococcus, pneumococcus macrolide resistance genes.
|
Ages Eligible for Study: | 180 Days and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | Yes |
Sampling Method: | Non-Probability Sample |
children with community-acquired pneumonia presenting to the Children's Hospital of Eastern Ontario emergency department
Inclusion Criteria:
Exclusion Criteria:
Contact: Jeffrey Pernica, MD | (613) 737 7600 ext 2651 | jpernica@cheo.on.ca |
Canada, Ontario | |
Children's Hospital of Eastern Ontario | |
Ottawa, Ontario, Canada, K1H 8L1 |
Principal Investigator: | Jeffrey Pernica, MD | Children's Hospital of Eastern Ontario/University of Ottawa |
Study Director: | Robert Slinger, MD | Children's Hospital of Eastern Ontario/University of Ottawa |
Responsible Party: | Children's Hospital of Eastern Ontario/University of Ottawa ( Jeffrey Pernica ) |
Study ID Numbers: | CHEO-ID-001 |
Study First Received: | March 23, 2009 |
Last Updated: | March 23, 2009 |
ClinicalTrials.gov Identifier: | NCT00867841 History of Changes |
Health Authority: | Canada: Health Canada |
pneumonia, community-acquired polymerase chain reaction pneumococcus |
mycoplasma chlamydophila anti-bacterial agents |
Anti-Infective Agents Anti-Bacterial Agents Respiratory Tract Infections Respiratory Tract Diseases |
Lung Diseases Mycoplasma Infections Pleuropneumonia Pneumonia |
Anti-Infective Agents Anti-Bacterial Agents Respiratory Tract Infections Respiratory Tract Diseases |
Therapeutic Uses Lung Diseases Pharmacologic Actions Pneumonia |